Catalyst Event
Hansoh Pharmaceutical Group Company Limited (3692) · Other
From Akros SCHK HK-Global Genomics Index (ASHGGENM)
4/29/2026, 12:00:00 AM
Announced on 2026-04-29 that its B7-H3 targeted ADC, HS-20093, was granted Breakthrough Therapy Designation by China's NMPA for treating advanced castration-resistant prostate cancer. Medium importance is assigned as Breakthrough Therapy Designation is a significant milestone likely impacting price by >=5%.
Korean Translation
2026-04-29에 자체 개발 B7-H3 표적 ADC HS-20093이 진행성 거세 저항성 전립선암 치료용으로 중국 국가약품감독관리국(NMPA)으로부터 혁신치료제 지정을 받았음을 발표함. 혁신치료제 지정은 중요한 이정표로 5% 이상의 주가 영향이 예상되어 'Medium'으로 분류함.
Related Recent Events
WuXi Biologics (Cayman) Inc (2269) · Other
The U.S. Office of Management and Budget (OMB) is scheduled to publish a full list of 'biotechnology companies of concern' (BCCs) by December 18, 2026, under the BIOSECURE Act; High importance is justified by the potential for severe regulatory risk causing a >10% price impact scheduled.
12/18/2026, 12:00:00 AM
Livzon Pharmaceutical Group Inc (1513) · Other
Ex-dividend date on June 16, 2026, for the 2025 final cash dividend of RMB 14.3 per 10 shares, with payment on July 13, 2026, scheduled. This consistent dividend payout is estimated to have a minor positive impact on investor sentiment.
6/16/2026, 12:00:00 AM
Grand Pharmaceutical Group Ltd (512) · Other
Ex-dividend date for a proposed final dividend of HK$0.169 per share for the year ended December 31, 2025, on 2026-06-12 scheduled. Low importance as dividend ex-dates typically result in minor price adjustments.
6/12/2026, 12:00:00 AM
Hangzhou Tigermed Consulting Co Ltd (3347) · Other
Annual General Meeting scheduled for June 2, 2026, to vote on the 2025 profit distribution plan, a final dividend of RMB 1.26 per 10 shares, and a general mandate for the board to repurchase H-shares. Routine AGM and dividend announcement are likely to cause a price impact of 1% or more, scheduled.
6/2/2026, 12:00:00 AM
GRAIL Inc (GRAL) · Other
GRAIL to present additional data from the NHS-Galleri trial at the 2026 ASCO Annual Meeting on May 30, 2026, scheduled. High importance estimated as clinical data is a key valuation driver.
5/30/2026, 12:00:00 AM
ANTA Sports Products Limited (2020) · Other
Ex-dividend date for the final FY2025 dividend of HK$1.08 per share is scheduled for May 15, 2026.
5/15/2026, 12:00:00 AM